Key result
Ibuprofen lysine matches indomethacin for PDA closure in premature neonates, with fewer adverse effects.
Why the study?
Indomethacin has been the drug of choice for PDA treatment but has undesirable adverse effects, prompting the search for alternative agents like ibuprofen lysine.
Is ibuprofen lysine as effective as indomethacin for the closure of patent ductus arteriosus in premature neonates?
Population
Premature neonates with clinically significant PDA
Comparison
Ibuprofen lysine vs indomethacin
Design
Review
Authors
Loading...
May support ibuprofen lysine preference for neonatal PDA; leaves open need for randomized confirmation before practice change.
Is ibuprofen lysine as effective as indomethacin for the closure of patent ductus arteriosus in premature neonates?
Ibuprofen lysine is an effective alternative to indomethacin for closing patent ductus arteriosus in premature neonates, offering a better safety profile.
Grace Poon (2007) conducted a review in Patent ductus arteriosus. Ibuprofen lysine (NeoProfen) vs. Indomethacin was evaluated on Closure of patent ductus arteriosus. Ibuprofen lysine is as effective as indomethacin for the closure of clinically significant patent ductus arteriosus in premature neonates, with fewer adverse effects.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: